Details of the Drug

General Information of Drug (ID: DMGL19D)

Drug Name

Enzalutamide

Synonyms

MDV3100; Enzalutamide (AR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Sequence

5'-CTCCAACATCAAGGAAGATGGCATTTCTAG

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

464.4

Logarithm of the Partition Coefficient (xlogp)

3.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 5.8 days (in patients) [2]
Metabolism: The drug is metabolized via the hepatic []
Vd: The volume of distribution (Vd) of drug is 110 L []

Chemical Identifiers

Formula: C21H16F4N4O2S
IUPAC Name: 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
Canonical SMILES: CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI: InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
InChIKey: WXCXUHSOUPDCQV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 15951529
ChEBI ID: CHEBI:68534
CAS Number: 915087-33-1
DrugBank ID: DB08899
TTD ID: D0QK5X
ACDINA ID: D01051

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acyl-coenzyme A synthetase ACSM1, mitochondrial (ACSM1)	OT1TS9M9	ACSM1_HUMAN	Gene/Protein Processing	[4]
AF4/FMR2 family member 3 (AFF3)	OTR0705Z	AFF3_HUMAN	Gene/Protein Processing	[4]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1)	OT3JQD99	SIA7A_HUMAN	Gene/Protein Processing	[4]
Alpha-protein kinase 2 (ALPK2)	OTWZZDQ9	ALPK2_HUMAN	Gene/Protein Processing	[4]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Gene/Protein Processing	[5]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[6]
Annexin A4 (ANXA4)	OTUCRYXL	ANXA4_HUMAN	Gene/Protein Processing	[5]
Aspartate aminotransferase, cytoplasmic (GOT1)	OTZLM5UB	AATC_HUMAN	Gene/Protein Processing	[5]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Gene/Protein Processing	[4]
Beta-microseminoprotein (MSMB)	OTYORAJC	MSMB_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Prostate cancer

ICD Disease Classification

2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Enzalutamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Darolutamide	DMV7YFT	Major	Increased metabolism of Enzalutamide caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[8]
-----------

Coadministration of a Drug Treating the Disease Different from Enzalutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[9]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Enzalutamide caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[10]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Major	Increased metabolism of Enzalutamide caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[11]
Ivabradine	DM0L594	Major	Increased metabolism of Enzalutamide caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[9]
Bedaquiline	DM3906J	Major	Increased metabolism of Enzalutamide caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[9]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Levalbuterol.	Asthma [CA23]	[12]
ABT-492	DMJFD2I	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by ABT-492.	Bacterial infection [1A00-1C4Z]	[13]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Enzalutamide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[14]
Erdafitinib	DMI782S	Major	Increased metabolism of Enzalutamide caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[15]
Pexidartinib	DMS2J0Z	Major	Decreased metabolism of Enzalutamide caused by Pexidartinib mediated inhibition of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[16]
HKI-272	DM6QOVN	Major	Increased metabolism of Enzalutamide caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
LY2835219	DM93VBZ	Major	Increased metabolism of Enzalutamide caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Esterified estrogens	DM9KZDO	Moderate	Increased metabolism of Enzalutamide caused by Esterified estrogens mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Tucatinib	DMBESUA	Major	Increased metabolism of Enzalutamide caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Major	Increased metabolism of Enzalutamide caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Alpelisib	DMEXMYK	Major	Increased metabolism of Enzalutamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Macitentan	DMP79A1	Major	Increased metabolism of Enzalutamide caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[22]
PF-04449913	DMSB068	Major	Increased metabolism of Enzalutamide caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[23]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[12]
Intedanib	DMSTA36	Moderate	Increased metabolism of Enzalutamide caused by Intedanib mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[13]
Levonorgestrel	DM1DP7T	Moderate	Increased metabolism of Enzalutamide caused by Levonorgestrel mediated induction of CYP450 enzyme.	Contraceptive management [QA21]	[19]
Osilodrostat	DMIJC9X	Major	Increased metabolism of Enzalutamide caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[9]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Enzalutamide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[14]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Enzalutamide caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[25]
OPC-34712	DMHG57U	Moderate	Increased metabolism of Enzalutamide caused by OPC-34712 mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[26]
Empagliflozin	DMRF9YK	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Empagliflozin.	Diabetes mellitus [5A10]	[13]
Polatuzumab vedotin	DMF6Y0L	Minor	Increased metabolism of Enzalutamide caused by Polatuzumab vedotin mediated induction of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[17]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Deutetrabenazine.	Dystonic disorder [8A02]	[9]
Ingrezza	DMVPLNC	Major	Increased metabolism of Enzalutamide caused by Ingrezza mediated induction of CYP450 enzyme.	Dystonic disorder [8A02]	[27]
Stiripentol	DMMSDOY	Major	Increased metabolism of Enzalutamide caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[9]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Enzalutamide caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[14]
Cannabidiol	DM0659E	Moderate	Increased metabolism of Enzalutamide caused by Cannabidiol mediated induction of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[9]
Bay 80-6946	DMLOS5R	Major	Increased metabolism of Enzalutamide caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[28]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Enzalutamide caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[29]
Ripretinib	DM958QB	Major	Increased metabolism of Enzalutamide caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[30]
Avapritinib	DMK2GZX	Major	Increased metabolism of Enzalutamide caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[9]
PSI-7977	DMLSUWZ	Major	Accelerated clearance of Enzalutamide due to the transporter induction by PSI-7977.	Hepatitis virus infection [1E50-1E51]	[17]
Daclatasvir	DMSFK9V	Major	Increased metabolism of Enzalutamide caused by Daclatasvir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[9]
MK-1439	DM215WE	Major	Increased metabolism of Enzalutamide caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Fostemsavir	DM50ILT	Major	Increased metabolism of Enzalutamide caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Cobicistat	DM6L4H2	Major	Increased metabolism of Enzalutamide caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Dolutegravir	DMCZGRE	Minor	Increased metabolism of Enzalutamide caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Elvitegravir	DMG9B1U	Major	Increased metabolism of Enzalutamide caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Aliskiren	DM1BV7W	Moderate	Increased metabolism of Enzalutamide caused by Aliskiren mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Levamlodipine	DM92S6N	Major	Increased metabolism of Enzalutamide caused by Levamlodipine mediated induction of CYP450 enzyme.	Hypertension [BA00-BA04]	[34]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Enzalutamide caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[35]
TP-434	DM5A31S	Major	Increased metabolism of Enzalutamide caused by TP-434 mediated induction of CYP450 enzyme.	Infectious gastroenteritis/colitis [1A40]	[36]
Suvorexant	DM0E6S3	Major	Increased metabolism of Enzalutamide caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[37]
Tasimelteon	DMLOQ1V	Major	Increased metabolism of Enzalutamide caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[38]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Enzalutamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[11]
Naloxegol	DML0B41	Major	Increased metabolism of Enzalutamide caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[9]
Pemigatinib	DM819JF	Major	Increased metabolism of Enzalutamide caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[9]
Brigatinib	DM7W94S	Major	Increased metabolism of Enzalutamide caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Ceritinib	DMB920Z	Major	Increased metabolism of Enzalutamide caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[40]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Enzalutamide caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[41]
PF-06463922	DMKM7EW	Major	Increased metabolism of Enzalutamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Osimertinib	DMRJLAT	Major	Increased metabolism of Enzalutamide caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[17]
BIBW 2992	DMTKD7Q	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by BIBW 2992.	Lung cancer [2C25]	[43]
Pralsetinib	DMWU0I2	Major	Increased metabolism of Enzalutamide caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[44]
Capmatinib	DMYCXKL	Major	Increased metabolism of Enzalutamide caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[45]
Selpercatinib	DMZR15V	Major	Increased metabolism of Enzalutamide caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[9]
Artesunate	DMR27C8	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Artesunate.	Malaria [1F40-1F45]	[13]
Idelalisib	DM602WT	Major	Increased metabolism of Enzalutamide caused by Idelalisib mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[46]
GDC-0199	DMH0QKA	Major	Increased metabolism of Enzalutamide caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[47]
IPI-145	DMWA24P	Major	Increased metabolism of Enzalutamide caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[48]
Acalabrutinib	DM7GCVW	Major	Increased metabolism of Enzalutamide caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[49]
Ibrutinib	DMHZCPO	Major	Increased metabolism of Enzalutamide caused by Ibrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[9]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Enzalutamide caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[17]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Enzalutamide due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[17]
Trametinib	DM2JGQ3	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Trametinib.	Melanoma [2C30]	[13]
LGX818	DMNQXV8	Major	Increased metabolism of Enzalutamide caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[50]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Enzalutamide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[17]
Ubrogepant	DM749I3	Major	Increased metabolism of Enzalutamide caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[51]
Rimegepant	DMHOAUG	Major	Increased metabolism of Enzalutamide caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[52]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Enzalutamide and Siponimod.	Multiple sclerosis [8A40]	[17]
Deflazacort	DMV0RNS	Major	Increased metabolism of Enzalutamide caused by Deflazacort mediated induction of CYP450 enzyme.	Muscular dystrophy [8C70]	[9]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Enzalutamide caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[9]
Vorapaxar	DMA16BR	Major	Increased metabolism of Enzalutamide caused by Vorapaxar mediated induction of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[53]
Rolapitant	DM8XP26	Major	Increased metabolism of Enzalutamide caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[9]
Netupitant	DMEKAYI	Major	Increased metabolism of Enzalutamide caused by Netupitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[17]
Entrectinib	DMMPTLH	Major	Increased metabolism of Enzalutamide caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[54]
S-297995	DM26IH8	Major	Increased metabolism of Enzalutamide caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[55]
Olaparib	DM8QB1D	Major	Increased metabolism of Enzalutamide caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[17]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Rucaparib.	Ovarian cancer [2C73]	[9]
MK-4827	DMLYGH4	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by MK-4827.	Ovarian cancer [2C73]	[56]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Triclabendazole.	Parasitic worm infestation [1F90]	[9]
Istradefylline	DM20VSK	Major	Increased metabolism of Enzalutamide caused by Istradefylline mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[57]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Enzalutamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[58]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Enzalutamide caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[59]
Lefamulin	DME6G97	Major	Increased metabolism of Enzalutamide caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[60]
Selexipag	DMAHSU0	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Selexipag.	Pulmonary hypertension [BB01]	[13]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Enzalutamide caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[61]
Upadacitinib	DM32B5U	Major	Increased metabolism of Enzalutamide caused by Upadacitinib mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[62]
Voxelotor	DMCS6M5	Major	Increased metabolism of Enzalutamide caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[63]
LDE225	DMM9F25	Major	Increased metabolism of Enzalutamide caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[64]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Enzalutamide caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[9]
Larotrectinib	DM26CQR	Major	Increased metabolism of Enzalutamide caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
LEE011	DMMX75K	Major	Increased metabolism of Enzalutamide caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[65]
Pitolisant	DM8RFNJ	Major	Increased metabolism of Enzalutamide caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[9]
Pomalidomide	DMTGBAX	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Pomalidomide.	Systemic sclerosis [4A42]	[66]
Fostamatinib	DM6AUHV	Major	Increased metabolism of Enzalutamide caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[67]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Enzalutamide due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[68]
As-1670542	DMV05SW	Major	Increased metabolism of Enzalutamide caused by As-1670542 mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[69]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Enzalutamide and Lenvatinib.	Thyroid cancer [2D10]	[9]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Enzalutamide caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[70]
Fluticasone	DMGCSVF	Moderate	Increased metabolism of Enzalutamide caused by Fluticasone mediated induction of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[13]
Betrixaban	DM2C4RF	Moderate	Accelerated clearance of Enzalutamide due to the transporter induction by Betrixaban.	Venous thromboembolism [BD72]	[71]
-----------


⏷ Show the Full List of 109 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Butylated hydroxytoluene	E00336	31404	Antioxidant
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric oxide black	E00522	16211978	Colorant
Gelatin	E00630	Not Available	Other agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Sorbitan tristearate	E00516	17800859	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Hypromellose acetate succinate	E00696	Not Available	Coating agent; Solubilizing agent; Modified-release agent;Film/membrane-forming agent
--------------------


⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Enzalutamide 40mg tablet	40mg	Tablet	Oral
Enzalutamide 80mg tablet	80mg	Tablet	Oral
Enzalutamide 40mg capsule	40mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
5	NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
6	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
7	In silico and in vitro assessment of androgen receptor antagonists. Comput Biol Chem. 2021 Jun;92:107490. doi: 10.1016/j.compbiolchem.2021.107490. Epub 2021 Apr 23.
8	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
11	Canadian Pharmacists Association.
12	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
14	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
15	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
16	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
19	Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
20	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
21	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
22	Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
23	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
24	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25	Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
26	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
27	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
28	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
29	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
30	Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
31	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
32	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
33	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
34	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
35	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36	Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
37	Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
38	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
39	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
40	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
41	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
42	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43	Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
44	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
45	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
47	Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
48	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
49	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
51	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
52	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
53	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
54	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
55	Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
56	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
57	Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
58	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
59	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
60	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
62	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
63	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
64	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
65	Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
66	Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
67	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
68	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
69	Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
70	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
71	Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]